9 New 4-Star Stocks This Week
Abbott and US Bancorp are among the stocks that fell into undervalued territory.

Every Monday, get Morningstar’s insights on company news, the latest stock market trends, and in-depth company reports from our analysts. Sign up for our Stock Strategist newsletter here.
Once a week, we screen the US-listed stocks under Morningstar’s coverage for newly undervalued names—those whose prices have just fallen into ranges worthy of 4- or 5-star
The five new 4-star stocks with the largest market capitalization are:
The full list of new 4-star stocks can be found at the bottom of this story. All returns in this article are reported in the stock’s base currency, and all data is sourced from Morningstar Direct.
What Is the Morningstar Rating for Stocks?
The Morningstar Rating can help investors identify stocks that are truly undervalued or overvalued, cutting through the market noise. The rating is determined by three factors: a stock’s price, its
The Latest Stock Valuation Changes
The Morningstar US Market Index rose 4.64% over the past week as of April 17, leaving the overall US stock market moderately undervalued, hovering at a 5% discount to its fair value estimate on a market cap-weighted basis.
Of the 830 US-listed stocks covered by Morningstar analysts:
- 38% are undervalued, 40% are fairly valued, and 22% are overvalued.
- Nine are newly undervalued.
- 30 are newly overvalued.
- Zero moved from a 4-star rating to a 5-star rating.
- 10 moved from 5-star to 4-star ratings.
- None of the newly undervalued stocks jumped from a 3-star rating to a 5-star rating.
- 41 are no longer undervalued.
Metrics for This Week’s New 4-Star Stocks
Abbott
- Morningstar Rating: ★★★★
- Fair Value Estimate: $115.00
- Uncertainty Rating: Medium
Following a 2.88% loss over the past week, medical device company Abbott saw its Morningstar Rating move to 4 stars from 3. Abbott has lost 20.00% over the past three months and 24.57% over the past year. The large-value stock has a narrow economic moat. Abbott is trading at a 16% discount to its fair value estimate of $115 per share, with an Uncertainty Rating of Medium.
US Bancorp
- Morningstar Rating: ★★★★
- Fair Value Estimate: $63.00
- Uncertainty Rating: Medium
Regional bank US Bancorp climbed 2.28% over the past week. The company’s stock is up 5.70% over the past three months and 55.32% over the past year. The stock’s fair value estimate rose to $63 per share from $59 during the week. It ended the week trading at a 10% discount to its new fair value estimate, with an Uncertainty Rating of Medium. The large-value stock has a wide economic moat.
Compass Group
- Morningstar Rating: ★★★★
- Fair Value Estimate: $31.50
- Uncertainty Rating: Medium
Restaurant firm Compass gained 3.12% over the past week, shifting its Morningstar Rating to 4 stars from 3. Compass has dropped 7.28% over the past three months and 14.67% over the past year. The stock is trading at a 10% discount to its fair value estimate of $31.50 per share, with an Uncertainty Rating of Medium. Compass is a large-core company with a narrow economic moat.
Hershey
- Morningstar Rating: ★★★★
- Fair Value Estimate: $218
- Uncertainty Rating: Low
Following a 4.78% loss over the past week, confectioner Hershey saw its Morningstar Rating move to 4 stars from 3. Hershey has lost 1.95% over the past three months and has gained 19.21% over the past year. The mid-core stock has a wide economic moat. Hershey is trading at a 12% discount to its fair value estimate of $218 per share, with an Uncertainty Rating of Low.
Imperial Brands
- Morningstar Rating: ★★★★
- Fair Value Estimate: $44.00
- Uncertainty Rating: Medium
Tobacco company Imperial dropped 8.44% over the past week, bumping its Morningstar Rating to 4 stars from 3. The company’s stock is down 5.56% over the past three months and is up 1.45% over the past year. The stock’s price is 14% below its fair value estimate of $44 per share, with an Uncertainty Rating of Medium. The large-value stock has a wide economic moat.
This article was generated with the help of automation and reviewed by Morningstar editors. Learn more about Morningstar’s use of automation.
The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.
